ArticleLeukemia2017

Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.

J Deng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.